Cervical Ca PROs in Clinical Practice

Status Completed

Clinical Trial Summary

Concurrent chemo-radiotherapy followed by intracavitary brachytherapy is standard of care for patients with locally advanced cervical cancer. Although curative, this treatment is challenging and leaves a significant proportion of women with severe toxicity, negatively impacting their quality of life. Although most recover over time, a proportion of women do not. Therefore, evaluation of quality of life becomes increasingly more important as cancer specific outcomes improve. One such method is through patient-reported outcomes (PROs), defined as "any report coming directly from the patient about a health condition and its treatment." This prospective multi-institutional study, involving the Princess Margaret (PM), Odette Regional Cancer Centre(ORCC) and Royal Victoria Regional Health Center (RVH), will assess to feasibility and acceptability of integrating a cervical cancer specific PRO measurement tool into clinical practice. Cervical cancer patients coming for follow-up appointments will be asked to complete the EORTC QLQ-CX24, a validated cervical cancer specific PRO questionnaire. At the end of the study period, Feedback Forms will be completed by participating patients and health care providers to obtain their perspectives regarding the feasibility and acceptability of incorporating the instrument into clinical practice. Future directions include designing an electronic platform and expanding its use in cervical cancer clinics provincially and nationally. The data collected should help identify disease-related symptoms, treatment-related toxicities, facilitate patient-physician communication, shared treatment planning and target intervention strategies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03048435
Study type	Observational
Source	University Health Network, Toronto
Contact
Status	Completed
Phase
Start date	February 27, 2017
Completion date	May 25, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06223308` - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03367871` - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer	Phase 2
Active, not recruiting	`NCT04537156` - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 3
Recruiting	`NCT03668639` - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin	Phase 2/Phase 3
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT04806945` - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer	Phase 3
Active, not recruiting	`NCT04185389` - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Completed	`NCT05120167` - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy	N/A
Recruiting	`NCT05483491` - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer	Phase 1
Recruiting	`NCT05736588` - Elimisha HPV (Human Papillomavirus)	N/A
Completed	`NCT05862844` - Promise Women Project	N/A
Recruiting	`NCT04934982` - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)	N/A
Recruiting	`NCT03876860` - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis	N/A
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Completed	`NCT00543543` - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)	Phase 3
Terminated	`NCT04864782` - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer	Phase 2/Phase 3
Recruiting	`NCT04226313` - Self-sampling for Non-attenders to Cervical Cancer Screening	N/A